Parkinson’s disease is a progressive neurodegenerative disorder which results in depletion of dopamine within the substantia nigra pars compacta in the central nervous system.
Featured Learning Zones
Parkinson’s disease primarily affects the motor system causing the classical symptoms of bradykinesia, tremor and rigidity. In addition, Parkinson’s disease results in non-motor symptoms such as depression and dementia which can worsen over time.
The exact cause of Parkinson’s disease is unknown and there are no disease-modifying treatments. However, dopaminergic pharmacotherapies designed to restore depleted dopamine in the brain are the mainstay of treatment. These include levodopa, dopamine agonists and monoamine oxidase B (MAO-B) inhibitors.
As Parkinson’s disease progresses, motor complications emerge related to long-term symptomatic treatment. This requires more frequent dosing or the addition of other therapies, such as catechol-O-methyltransferase (COMT) inhibitors.
Visit our dedicated Parkinson’s disease Learning Zone for learning resources on diagnosing motor fluctuations, treatment guidelines and the available COMT inhibitors.
Related news and insights
Addex Pharma reports positive top line data from a Phase IIa clinical study of dipraglurant in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia (LID). The data show that dipraglurant met the primary objective of the study by exhibiting a good safety and tolerability profile.
Yumanity Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into definitive agreements for a strategic transaction.
AbbVie announced that it has submitted a New Drug Application (NDA) to the FDA for ABBV 951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).